Amgen’s Evolocumab Study Completes: A New Era in Cardiovascular Prevention?

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.

Amgen Inc. recently completed a significant clinical study titled A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke. The study aimed to assess the effect of evolocumab, a cholesterol-lowering drug, on major cardiovascular events in adults at high risk but without a prior heart attack or stroke. This research is crucial as it explores preventive measures for cardiovascular diseases in high-risk populations.

The intervention tested in this study was evolocumab, a drug administered via subcutaneous injection every two weeks. Evolocumab is designed to lower low-density lipoprotein cholesterol (LDL-C), which is often linked to cardiovascular events. The study also included a placebo group for comparison.

This Phase 3 study was interventional, with participants randomly allocated to either the evolocumab or placebo group. It followed a parallel intervention model with quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor were unaware of the group assignments. The primary purpose of the study was treatment-focused.

The study began on June 11, 2019, and was completed with the last update submitted on August 13, 2025. These dates are significant as they mark the timeline of the study’s progress and the availability of its findings.

The completion of this study could have positive implications for Amgen’s stock performance, as successful results may boost investor confidence and market share in the cardiovascular treatment sector. Competitors in the pharmaceutical industry will likely monitor these developments closely, as evolocumab could set a new standard in preventive cardiovascular care.

The study is now completed, and further details can be accessed on the ClinicalTrials portal.